The WHO international drug monitoring programme

Side Effects of Drugs Annual

Volumn 25, Issue , 2002, Pages 589-598

  Ralph Edwards, I ^a   Olsson, Sten ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0043217871     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(02)80057-5     Document Type: Article

References (31)

1. Public report CIOMS Harmonization of data fields for electronic transmission of case-report information internationally 1995 CIOMS Geneva
2. Orre R Lansner A Bate A Lindquist M Bayesian neural networks with confidence estimations applied to data mining Comput Stat Data Analysis 34 2000 473 493
3. Bate A Lindquist M Edwards IR Olsson S Orre R Lanser A De Freitas RM A Bayesian neural network method for adverse drug reaction signal generation Eur J Clin Pharmacol 54 1998 315 321
4. Lindquist M Edwards IR Bate A Fucik H Nunes AM Ståhl M From Association to Alert-a revised approach to International Signal Analysis Pharmacoepidemiol Drug Saf 8 1999 S15 S25
5. Lindquist M Ståhl M Bate A Edwards IR Meyboom RHB A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database Drug Saf 23 2000 533 542
6. (Sci) Lindquist M ATC—a useful tool in ADR monitoring Pharm Weekbl 9 1987 331
7. Lindquist M Edwards IR The WHO Programme for International Drug Monitoring its database, and the technical support of the Uppsala Monitoring Center J J Rheumatol 28 2001 1180 1187
8. Lindquist M The WHO Programme for International Drug Monitoring: the Present and Future Mitchard M Electronic Communication Technologies 1998 Interpharm Press Inc BuffalO Grove 527 549
9. Lindquist M Edwards IR Risks of nonsedating antihistamines Lancet 349 1997 1322
10. Lindquist M Pettersson M Edwards IR Sanderson J Taylor N Fletcher P Schou J Fraunfelder FT Omeprazole and visual disorders: seeing alternatives Pharmacoepidemiol Drug Saf 5 1996 27 32
11. Lindquist M Pettersson M Edwards IR Sanderson J Taylor N Fletcher P Schou JS Savage R How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data Pharmacol Toxicol 80 1997 211 217
12. Lindquist M Sanderson J Claesson C Imbs JL Rohan A Edwards IR New pharmacovigilance information on a old drug—an international study of spontaneous reports on digoxin Drug Invest 8 1994 73 80
13. Olsson S Support to developing countries from the WHO Drug Monitoring Centre Abstracts from the DIA 30th Annual Meeting Washington DC 5–9 June 1994 103
14. Olsson S The role of the WHO Programme on International Drug Monitoring in coordinating worldwide drug safety efforts Drug Saf 19 1998 1 10
15. Olsson S National Pharmacovigilance Systems: Uppsala Monitoring Centre 2nd edition 1999 The Uppsala Monitoring Centre Uppsala
16. Edwards IR Monitoring the safety of herbal remedies: WHO project is under way Br Med J 311 1995 1569 1570
17. Farah MH Consumer protection and herbal remedies WHO Drug Inf 12 1998 141
18. Farah MH Edwards IR Lindquist M Leon C Shaw D International monitoring of adverse health effects associated with herbal medicines Pharmacoepidemiol Drug Saf 9 2000 105 112
19. Fucik H Farah MH Meyboom RHB Lindquist M Edwards IR Olsson S Vigilance of herbal medicines at the Uppsala Monitoring Centre Minerva Med 92 2001 24 26
20. Report No. 9290360712 CIOMS Reporting of adverse drug reactions: definitions of terms and criteria for their use 1999 CIOMS Geneva
21. Edwards IR Biriell C Harmonisation in pharmacovigilance Drug Saf 10 1994 93 102
22. Edwards IR Aronson JK Adverse drug reactions: definitions, diagnosis, and management Lancet 356 2000 1255 1259
23. Edwards IR Lindquist M Understanding and communication of key concepts in therapeutics Velo G Moments of truth-communicating drug safety 2000 Elsevier Science Verona
24. Edwards IR Wiholm B-E Martinez C Concepts in risk-benefit assessment Drug Saf 15 1996 1 7
25. CIOMS Benefit-risk balance for marketed drugs: evaluating safety signlas 1st edition 1998 World Health Organization Geneva
26. Edwards IR Hugman B The challenge of effectively communicating risk-benefit information Drug Saf 17 1997 216 227
27. Edwards IR Who cares about pharmacovigilance? Eur J Clin Pharmacol 53 1997 83 88
28. Edwards IR Spontaneous reporting-of what? Clinical concerns about drugs Br J Clin Pharmacol 48 1999 138 141
29. Edwards IR The accelerating need for pharmacovigilance J R Coll Phys London 34 2000 48 51
30. Biriell C Edwards IR Reasons for reporting adverse drug reactions—some thoughts based on an international review Pharmacoepidemiol Drug Saf 6 1997 21 26
31. Edwards IR Fucik H Impact and credibility of the WHO adverse reaction signals Drug Inf J 30 1996 461 464